“๐๐ง ๐ญ๐จ๐๐๐ฒ’๐ฌ ๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฏ๐ ๐ฆ๐๐ซ๐ค๐๐ญ, ๐ข๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐ข๐ฌ ๐ ๐๐ซ๐ข๐ญ๐ข๐๐๐ฅ ๐ฌ๐ญ๐๐ฉ ๐ข๐ง ๐ข๐๐๐ง๐ญ๐ข๐๐ฒ๐ข๐ง๐ ๐ญ๐ก๐ ๐๐จ๐ซ๐ซ๐๐๐ญ ๐ญ๐๐ซ๐ ๐๐ญ ๐๐จ๐ง๐ฌ๐ฎ๐ฆ๐๐ซ๐ฌ ๐๐ง๐ ๐ฉ๐ซ๐จ๐ฏ๐ข๐๐ข๐ง๐ ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ฌ๐๐ ๐ฌ๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ ๐๐จ๐ซ ๐ญ๐ก๐๐ข๐ซ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐ง๐๐๐๐ฌ. ๐๐ก๐ข๐ฅ๐ ๐๐จ๐ซ๐ฆ๐ฎ๐ฅ๐๐ญ๐ข๐ง๐ ๐ญ๐ก๐๐ฌ๐ ๐ฌ๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ, ๐๐ฏ๐๐ซ๐ฒ ๐๐๐๐๐ญ ๐๐ง๐ ๐ฌ๐ฉ๐๐๐ข๐๐ข๐ ๐ฉ๐ซ๐จ๐๐ฅ๐๐ฆ ๐ฉ๐ซ๐๐ฌ๐๐ง๐ญ๐๐ ๐๐ฒ ๐ญ๐ก๐ ๐ฉ๐๐ซ๐ญ๐ข๐๐ฎ๐ฅ๐๐ซ ๐ฌ๐๐๐ญ๐จ๐ซ ๐ข๐ฌ ๐ญ๐ก๐จ๐ซ๐จ๐ฎ๐ ๐ก๐ฅ๐ฒ ๐๐จ๐ง๐ฌ๐ข๐๐๐ซ๐๐. ๐๐ญ ๐๐ฅ๐ฌ๐จ ๐๐จ๐ง๐ฌ๐ข๐๐๐ซ๐ฌ ๐ง๐ฎ๐ฆ๐๐ซ๐จ๐ฎ๐ฌ ๐ ๐จ๐ฏ๐๐ซ๐ง๐ฆ๐๐ง๐ญ ๐ซ๐๐๐จ๐ซ๐ฆ๐ฌ, ๐ญ๐ก๐ ๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฏ๐ ๐๐ง๐ฏ๐ข๐ซ๐จ๐ง๐ฆ๐๐ง๐ญ, ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐๐ซ ๐๐๐ก๐๐ฏ๐ข๐จ๐ฎ๐ซ, ๐๐ฎ๐ซ๐ซ๐๐ง๐ญ ๐๐ง๐ ๐๐ฎ๐ญ๐ฎ๐ซ๐ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐ฌ๐ญ๐ซ๐๐ญ๐๐ ๐ข๐๐ฌ, ๐๐ง๐ ๐ซ๐๐ฉ๐ข๐๐ฅ๐ฒ ๐๐ก๐๐ง๐ ๐ข๐ง๐ ๐ญ๐๐๐ก๐ง๐ข๐๐๐ฅ ๐๐ซ๐๐๐ค๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก๐ฌ. ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐๐ข๐๐ฌ ๐ข๐ง ๐ญ๐ก๐ ๐๐จ๐ซ๐ฆ๐ฎ๐ฅ๐๐ญ๐ข๐จ๐ง ๐จ๐ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐ฉ๐ฅ๐๐ง๐ฌ ๐๐ง๐ ๐ฉ๐จ๐ฅ๐ข๐๐ข๐๐ฌ.”
P2X7 Receptor Antagonist Market Insights
As a pain medication, a P2X7 Receptor Antagonist (or RA) is a drug that blocks the activity of this ligand in the brain. The P2X7 receptor is a key molecule in the initiation of inflammatory processes in the body. However, the mechanisms of P2X7 antagonists remain poorly understood, which hampers the development of effective therapies for patients suffering from chronic pain.
In the disease model of SODG93A mice, a P2X7R antagonist has been shown to slow down the progression of ALS. In a study in which BBG was administered intraperitoneally at 45.5 mg/kg every 48 hours, the drug was found to improve motor performance more in males than in females, but had no effect on survival. As with other drugs, P2X7 Receptor Antagonists should only be used after thorough research.
The mechanism of action of a P2X7 Receptor Antagonist is unknown, but the research suggests that it prevents the retraction of the drug-binding pocket and the formation of turret-like architecture during channel opening. These findings will help guide the development of P2X7-specific drugs. In the meantime, these new compounds can help patients manage pain by enhancing their immune systems.
To Get more information Request for Sample Report at โ https://www.coherentmarketinsights.com/insight/request-sample/2595
Increasing use of P2X7 receptor antagonists in treatment of various diseases is driving the global P2X7 receptor antagonist market growth
Various research studies reported activation of P2X7 channels owing to release of pro-inflammatory cytokines IL-1b and IL-18. As adenosine triphosphate (ATP) has lowest affinity for P2X7 among all other purinergic ion channels (P2X4, P2X3, and others), extracellular ATP rarely activates P2X7 channel. P2X7 receptor antagonists have significant therapeutic potential, as P2X7 receptors have been found to be associated with regulation of inflammation, and all immune cell types (lymphocytes, macrophages, monocytes, and others) express P2X7R. Moreover, P2X7 ion channel has been directly linked to major depression and animal studies have shown that antagonism of P2X7 with centrally penetrant antagonists resulted in antidepressant-like behavior in animal models. Thus, inflammation, pain indications, mood disorders, and depression are the potential areas among others where, P2X7 is involved, and its antagonism can modify disease outcomes, or can be a disease-modifying therapy. As such, P2X7 is an ideal drug target as antagonism of P2X7 channel would not cause any serious side effects, as antagonism will only start when the channel is activated by high ATP concentrations, believed to happen during pathology of neuroinflammatory disorders of the Central Nervous System (CNS) such as stroke, epilepsy, multiple sclerosis, chronic neurodegenerative, and neuropsychiatric diseases. These factors are expected to support global P2X7 receptor antagonist market growth over the forecast period.
The global P2X7 receptor antagonist market size was US$ 96.6 million in 2024, and is expected to witness a robust CAGR of 18.3% over the forecast period (2024โ2026).
Get Free PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/2595
Robust early stage pipeline is projected to uplift the global P2X7 receptor antagonist market growth
Key manufacturer such as GlaxoSmithKline Plc, Johnson and Johnson, AstraZeneca plc, Asahi Kasei Corporation, and others have potential molecules in the pipeline.
Asahi Kasei Corporation, AstraZeneca Plc, and RaQualia Pharma Inc. have their products in preclinical stages for various indications such as analgesics, inflammation, and other indications.
GlaxoSmithKline Plc, Johnson & Johnson, and Evotec AG have these molecule for indications such as pain conditions, inflammatory conditions, major depressive disorder, and mood disorders.
Although, these molecules are in early stages of development, and faster clinical trials and active interest by companies such as Evotec AG, and Asahi Kasei Pharma to advance the pipeline is projected to support growth of the global P2X7 receptor antagonists market.
However, leading international manufacturers such as GlaxoSmithKline Plc. and AstraZeneca Plc. have not been actively pursuing the advancement of P2X7 receptor antagonist category. For instance, GlaxoSmithKline Plcโs P2X7 candidate GSK1482160 is still in Phase 1 clinical trials and the study ended in April 2009. Moreover, the category has less number of candidates in the pipeline as compared to other conditions such as cancer and others. This factor has affected global P2X7 receptor antagonist market growth.
Some of the key players operating in the global P2X7 receptor antagonist market include, GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc, RaQualia Pharma, Evotec AG, and Asahi Kasei Corporation.
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/2595
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 P2X7 Receptor Antagonists Market Market Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: P2X7 Receptor Antagonists Market Market Industry Impact
Chapter 2 P2X7 Receptor Antagonists Market Market Competition by Types, Applications, and Top Regions and Countries
2.1 P2X7 Receptor Antagonists Market Market (Volume and Value) by Type
2.3 P2X7 Receptor Antagonists Market Market (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 P2X7 Receptor Antagonists Market Market Sales, Consumption, Export, Import by Regions
Chapter 5 North America P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 6 East Asia P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 7 Europe P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 8 South Asia P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 9 Southeast Asia P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 10 Middle East P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 11 Africa P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 12 Oceania P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 13 South America P2X7 Receptor Antagonists Market Market Market Analysis
Chapter 14 Company Profiles and Key Figures in P2X7 Receptor Antagonists Market Market Business
Chapter 15 P2X7 Receptor Antagonists Market Market Market Forecast (2021-2028)
Chapter 16 Conclusions
Research Methodologyโฆ.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837